|

IPN01203 Clinical Trials

1 actively recruiting trial across 1 location

No change since August 2026

Pipeline

Phase 1/2: 1

Top Sponsors

  • Ipsen1

Indications

  • Metastatic Solid Tumor1
  • Advanced Solid Tumor1
  • Cancer1

Grand Rapids, Michigan1 trial

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

South Texas Accelerated Research Therapeutics (START) - Midwest

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.